# US Blood Testing Market

> United States Blood Testing Market Research Report: Size, Share, Trend Analysis - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 7.59%
- **2024:** $ 27.5 Billion
- **2025:** $ 29.59 Billion
- **2035:** $ 61.5 Billion
- **Key Players:** Abbott Laboratories (US), Roche Diagnostics (CH), Siemens Healthineers (DE), Thermo Fisher Scientific (US), Danaher Corporation (US), Becton Dickinson and Company (US), Ortho Clinical Diagnostics (US), Bio-Rad Laboratories (US)

**Report ID:** MRFR/LS/14182-HCR · **Pages:** 100 · **Author:** Vikita Thakur & Garvit Vyas · **Last Updated:** July 29, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-blood-testing-market-15709

---

## Market Summary

## US Blood Testing Market Highlighted Trends & Dynamics

The US blood testing market has witnessed substantial growth in recent years, fueled by advancements in medical technology, rising awareness about preventive healthcare, and an aging population. This dynamic sector plays a pivotal role in disease diagnosis, monitoring, and overall healthcare management.

The growth of the market is very much connected to new technology changes. The arrival of modern check-up machines, like testing for genes and molecules, changed how blood tests are done. These tools not only make diagnoses more accurate but also allow for special treatment plans based on the person.

The rise in long-term sicknesses, like diabetes and heart problems is helping to make blood testing services more needed. Blood tests are important tools to find and control these health problems. They always need testing services.

More people are choosing to have regular blood tests. This is because there's more focus on staying healthy and finding any health problems early before they get worse. This early action lets us step in quickly and stop problems before they happen, helping to save money on healthcare costs overall.

The big increase in at-home testing has been a major change in the US market for blood tests. Point-of-care tests give quick results, letting doctors make immediate medical choices. This has been very helpful in emergency situations, basic care and remote healthcare areas.

The COVID-19 pandemic shows how important it is to have strong testing equipment. Blood tests were very important for finding out if someone had COVID-19 and keeping track of their health when they got sick. The pandemic has made people realize how important regular health check-ups are. This also increased the demand for blood tests.

There has been a big change towards using blood test kits at home. More and more, people want to take tests at home instead of going somewhere else. Businesses that provide tests people can do at home are becoming popular. They let users get these services quickly and easily.

Even though it's grown, the US blood testing market has problems with rules and payments. It also worries about keeping data safe. But, these problems also offer chances for new ideas and teamwork between health care workers, rule makers and technology creators.

Telemedicine has become a big reason for growth in the blood testing market. Online check-ups and healthcare services help people get blood tests more easily, especially those living in rural or underprivileged areas. This can help fix health care differences and make overall healthcare better.

The future of the US blood testing market looks promising, with continuous advancements in technology, increasing healthcare awareness, and a shift towards personalized medicine. Collaboration between healthcare stakeholders, research institutions, and technology companies is likely to drive further innovation, ensuring the market's sustained growth.

## Market Drivers

### Rising Incidence of Chronic Diseases

The increasing prevalence of chronic diseases in the US is a primary driver for the blood testing market. Conditions such as diabetes, cardiovascular diseases, and cancer necessitate regular monitoring and testing. According to the Centers for Disease Control and Prevention (CDC), approximately 6 in 10 adults in the US have a chronic disease, which underscores the demand for effective blood testing solutions. This trend is likely to propel the blood testing market as healthcare providers seek to implement routine testing protocols to manage these conditions effectively. Furthermore, the financial burden associated with chronic diseases, estimated at over $3.7 trillion annually, emphasizes the need for early detection and management, thereby driving growth in the blood testing market.

### Increased Focus on Personalized Medicine

The shift towards personalized medicine is significantly influencing the blood testing market. As healthcare evolves, there is a growing emphasis on tailoring treatments based on individual patient profiles, which often requires comprehensive blood testing. This approach not only enhances treatment efficacy but also minimizes adverse effects. The market for personalized medicine is projected to reach $2.4 trillion by 2025, indicating a robust growth trajectory. Blood tests play a crucial role in this paradigm shift, providing essential data that informs treatment decisions. Consequently, the blood testing market is likely to expand as healthcare providers increasingly adopt personalized approaches to patient care.

### Technological Innovations in Testing Methods

Technological advancements in blood testing methods are transforming the landscape of the blood testing market. Innovations such as point-of-care testing, liquid biopsy, and advanced diagnostic tools are enhancing the accuracy and speed of blood tests. For instance, the introduction of microfluidics technology has enabled rapid testing with minimal sample volumes, which is particularly beneficial in emergency settings. The blood testing market is expected to grow at a CAGR of 6.5% from 2025 to 2030, driven by these technological innovations. As healthcare providers seek to improve patient outcomes and streamline testing processes, the adoption of these advanced technologies is likely to accelerate.

### Growing Demand for Home-Based Testing Solutions

The increasing demand for home-based testing solutions is reshaping the blood testing market. Patients are increasingly seeking convenience and autonomy in managing their health, leading to a rise in at-home blood testing kits. This trend is supported by advancements in technology that allow for accurate and reliable testing outside traditional laboratory settings. The home healthcare market is projected to reach $515 billion by 2027, indicating a substantial opportunity for blood testing solutions. As consumers prioritize ease of use and accessibility, the blood testing market is likely to experience significant growth in the development and distribution of home testing products.

### Regulatory Support for Innovative Testing Solutions

Regulatory support for innovative testing solutions is a crucial driver for the blood testing market. The US Food and Drug Administration (FDA) has been actively streamlining the approval process for new diagnostic tests, which encourages innovation and expedites the availability of advanced blood testing solutions. This regulatory environment fosters competition and drives investment in research and development within the blood testing market. As a result, companies are more inclined to introduce novel testing methods that meet regulatory standards, thereby enhancing the overall market landscape. The positive regulatory climate is likely to stimulate growth and innovation in the blood testing market.

## Future Outlook

The [Blood Testing Market](https://www.marketresearchfuture.com/reports/blood-testing-market-5797) is projected to grow at a 7.59% CAGR from 2025 to 2035, driven by technological advancements, increasing chronic diseases, and rising health awareness.

**New opportunities:**

- Development of mobile blood testing units for remote areas. Integration of AI for predictive analytics in diagnostics. Expansion of personalized medicine through targeted blood tests.

By 2035, the blood testing market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Type: Complete Blood Count (Largest) vs. Blood Glucose Tests (Fastest-Growing)

Complete Blood Count (CBC) dominates the segment of the US blood testing market, accounting for the largest share due to its fundamental role in routine health checks. Other tests like Blood Chemistry, Blood Glucose Tests, Coagulation Tests, and Blood Typing Tests, though significant, hold smaller market shares, with each providing specific insights into health conditions, thus creating a diversified testing landscape.

The growth in the segment is driven by increasing awareness of preventive healthcare and advancements in testing technologies. Blood Glucose Tests stand out as the fastest-growing category, reflecting a rise in diabetes prevalence and increased screening efforts. Moreover, the ongoing innovation in testing methodologies contributes significantly to the expansion of all types in this market.

Complete Blood Count (Dominant) vs. Blood Glucose Tests (Emerging)

Complete Blood Count (CBC) is a critical test used in routine health check-ups to evaluate overall health and detect a variety of disorders, such as anemia and infection. Its dominance in the US blood testing market is attributed to its comprehensive nature, providing essential data about blood components. Meanwhile, Blood Glucose Tests have emerged as essential tools for monitoring and managing diabetes, spurred by rising diabetes rates. As these tests become more accessible and precise, their adoption continues to grow, supported by health initiatives aimed at increasing awareness about diabetes management.

### By End User: Hospitals (Largest) vs. Diagnostic Laboratories (Fastest-Growing)

In the US blood testing market, Hospitals hold the largest share, driven by their comprehensive healthcare services and high patient volumes. This segment is pivotal for routine and emergency blood tests, catering to diverse health conditions and supporting critical care. Diagnostic Laboratories follow closely, experiencing significant demand for specialized testing services, which accelerates their growth in the market. Both segments are crucial, but their dynamics differ, with hospitals leading in volume and laboratories swimming in niche testing opportunities.

Growth trends in the US blood testing market are notably affected by advancements in technology, increasing incidences of chronic diseases, and a rising preference for early diagnosis. Home Care Settings are evolving as a notable segment, reflecting the shift towards patient-centric care. Research Institutions contribute to innovation and development, particularly in areas like personalized medicine and biomarker discovery, thereby driving the overall growth of this sector.

Hospitals: Dominant vs. Diagnostic Laboratories: Emerging

Hospitals represent the dominant end user segment in the US blood testing market, characterized by their capabilities to handle high volumes of tests due to substantial patient footfall and integrated healthcare services. They often utilize advanced diagnostic technologies and employ specialized laboratories to ensure timely and accurate results. In contrast, Diagnostic Laboratories are emerging as key players, focusing on specialized and high-complexity testing that meets the needs of healthcare providers and patients seeking precision diagnostics. This segment benefits from advancements in molecular testing and automation, enhancing testing speed and accuracy, thereby fostering growth in a competitive landscape.

### By Product: Reagents (Largest) vs. Software (Fastest-Growing)

The market share distribution of the product segment in the US blood testing market reveals that reagents hold the largest share, driven by their essential role in various testing procedures. Consumables and instruments follow, contributing significantly to the overall market landscape. Software solutions, while currently smaller in share, are gaining traction as healthcare facilities increasingly demand efficient data management and reporting systems for lab results. 

Growth trends indicate a substantial shift towards automation and digital solutions within the US blood testing market. The demand for software is rising rapidly due to the ongoing need for efficient workflow management and compliance with governmental regulations. Furthermore, newer reagents are being developed, enhancing the accuracy and speed of tests, ultimately driving the market's expansion.

Reagents (Dominant) vs. Software (Emerging)

Reagents are the backbone of the US blood testing market, recognized for their critical role in facilitating various diagnostic procedures. Their dominance is fueled by continuous advancements in formulation and effectiveness, ensuring reliable test results across a myriad of applications. In contrast, software solutions are considered emerging in this sector; they enhance operational efficiencies, streamline laboratory processes, and enable better data analytics. As laboratories strive for improved performance and accuracy, the integration of software with testing instruments is becoming essential, positioning software as a transformative player in the future of blood diagnostics.

## Competitive Benchmarking

The [blood testing](https://www.marketresearchfuture.com/reports/blood-testing-market-5797) market is characterized by a dynamic competitive landscape, driven by technological advancements, increasing demand for diagnostic testing, and a growing emphasis on personalized medicine. Major players such as Abbott Laboratories (US), Roche Diagnostics (CH), and Thermo Fisher Scientific (US) are at the forefront, each adopting distinct strategies to enhance their market positioning. Abbott Laboratories (US) focuses on innovation, particularly in point-of-care testing solutions, which allows for rapid diagnostics in various settings. Meanwhile, Roche Diagnostics (CH) emphasizes its extensive portfolio of laboratory instruments and reagents, aiming to integrate digital solutions into its offerings to improve efficiency and accuracy. Thermo Fisher Scientific (US) is pursuing a strategy of regional expansion, particularly in emerging markets, while also investing heavily in research and development to maintain its competitive edge. The blood testing market exhibits a moderately fragmented structure, with several key players influencing its dynamics. Companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency and reduce costs. This trend is particularly evident as firms seek to mitigate disruptions and ensure a steady supply of testing products. The collective influence of these major players shapes a competitive environment where innovation and operational excellence are paramount. In September 2025, Roche Diagnostics (CH) announced the launch of its new digital platform designed to streamline laboratory workflows and enhance data management capabilities. This strategic move is significant as it aligns with the growing trend towards digitalization in healthcare, enabling laboratories to improve efficiency and accuracy in test processing. By integrating advanced analytics and cloud-based solutions, Roche aims to position itself as a leader in the digital transformation of laboratory diagnostics. In October 2025, Abbott Laboratories (US) expanded its collaboration with a leading telehealth provider to enhance remote patient monitoring capabilities. This partnership is crucial as it reflects the increasing integration of telehealth services with diagnostic testing, allowing for more comprehensive patient care. By leveraging telehealth, Abbott seeks to improve access to testing and facilitate timely interventions, thereby enhancing patient outcomes and expanding its market reach. In August 2025, Thermo Fisher Scientific (US) completed the acquisition of a biotechnology firm specializing in next-generation sequencing technologies. This acquisition is strategically important as it allows Thermo Fisher to enhance its capabilities in genetic testing, a rapidly growing segment within the blood testing market. By integrating these advanced technologies, the company aims to offer more comprehensive testing solutions, catering to the rising demand for personalized medicine. As of November 2025, the blood testing market is witnessing trends such as digitalization, sustainability, and the integration of artificial intelligence (AI) into diagnostic processes. Strategic alliances among key players are increasingly shaping the competitive landscape, fostering innovation and collaboration. Moving forward, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological innovation, supply chain reliability, and the ability to deliver personalized healthcare solutions. This shift underscores the importance of agility and adaptability in a rapidly changing market.

## Report Scope

| MARKET SIZE 2024 | 27.5(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 29.59(USD Billion) |
| MARKET SIZE 2035 | 61.5(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.59% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Abbott Laboratories (US), Roche Diagnostics (CH), Siemens Healthineers (DE), Thermo Fisher Scientific (US), Danaher Corporation (US), Becton Dickinson and Company (US), Ortho Clinical Diagnostics (US), Bio-Rad Laboratories (US) |
| Segments Covered | Type, End User, Product |
| Key Market Opportunities | Integration of advanced diagnostics and personalized medicine in the blood testing market. |
| Key Market Dynamics | Technological advancements drive innovation in blood testing, enhancing accuracy and efficiency in diagnostics. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the overall market valuation of the US blood testing market in 2024?**
A: The overall market valuation of the US blood testing market was $27.5 Billion in 2024.

**Q: What is the projected market valuation for the US blood testing market by 2035?**
A: The projected market valuation for the US blood testing market is $61.5 Billion by 2035.

**Q: What is the expected CAGR for the US blood testing market during the forecast period 2025 - 2035?**
A: The expected CAGR for the US blood testing market during the forecast period 2025 - 2035 is 7.59%.

**Q: Which segment had the highest valuation in the US blood testing market in 2024?**
A: In 2024, the Blood Chemistry Tests segment had the highest valuation at $8.2 Billion.

**Q: What is the projected valuation for the Complete Blood Count segment by 2035?**
A: The projected valuation for the Complete Blood Count segment is $15.5 Billion by 2035.

**Q: Which end user segment is expected to grow the most by 2035?**
A: The Diagnostic Laboratories segment is expected to grow the most, reaching $20.0 Billion by 2035.

**Q: What was the valuation of the Reagents segment in 2024?**
A: The valuation of the Reagents segment was $8.25 Billion in 2024.

**Q: How much is the Instruments segment projected to be worth by 2035?**
A: The Instruments segment is projected to be worth $15.5 Billion by 2035.

**Q: Which key player is based in the US and is a leader in the blood testing market?**
A: Abbott Laboratories, based in the US, is a key player in the blood testing market.

**Q: What is the expected growth for the Home Care Settings segment by 2035?**
A: The Home Care Settings segment is expected to grow to $9.0 Billion by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-blood-testing-market-15709*